Brinter raises €1.2M to fund launch of scalable bioprinter in new markets

Raised via a seed funding round led by early-stage VC firm Innovestor, the capital is set to be used as a means of expanding the company’s operations, allowing it to more easily address the U.S. and European medical markets with its modular 3D bioprinter, which it says could have future organ fabrication applications. In practise, Brinter clients are able to use the company’s software to turn MRI, X-ray or CT scanning data into CAD models, before printing them into viable soft tissues for use within drug evaluations, in a way that could help accelerate the translation of new medicines into clinics and bring an end to the use of animal testing. “Brinter is an exciting addition to our portfolio as the company’s competitive advantages of multi-material printing capabilities, modularity, and scalability combined with their own easy-to-use software application were very convincing.” While transplantable bioprinted organs remain years away from reality, recent advances in the technology may have shortened this wait considerably. 3D Systems’ continued interest in bioprinting will no doubt hasten its development, and the firm reported “tremendous progress” within its dedicated Print to Perfusion program earlier this year. As part of a strategic refocus announced by the company in 2020, it has also sought to build on its core healthcare and industrial segments, and acquired Additive Works and bioprinting firm Allevi during May 2021, with this in mind.